← Back to Search

Patients with Small Cell Lung Cancer (SCLC) for Small Cell Lung Cancer

N/A
Recruiting
Led By Virginia Rhodes, MD
Research Sponsored by Tempus AI
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 years
Awards & highlights

Summary

The study is a non-interventional evaluation of participants with SCLC who will receive diagnostic and (where possible) post-progression tumor tissue profiling, alongside plasma ctDNA biomarker profiling in addition to their standard of care therapy and disease surveillance.

Eligible Conditions
  • Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To characterize relationship between tissue transcriptional subtype and clinical outcomes
To determine if tumor tissue transcriptional subtypes can be detected
Secondary outcome measures
To assess the potential for liquid biopsy in SCLC
To test which tissue and sample variables confound gene expression subtypes
Other outcome measures
To identify biomarkers and mechanisms of progression
To measure biomarkers of SCLC using the TEMPUS xT assay
To study progression free survival (PFS) and overall survival (OS)

Side effects data

From 2016 Phase 3 trial • 356 Patients • NCT00048997
31%
Fatigue (lethargy, malaise, asthenia)
23%
Alopecia
17%
Late RT Toxicity: Other: NOS
11%
Nausea
10%
Anorexia
9%
Late RT Toxicity: Brain: NOS
9%
Headache
7%
Late RT Toxicity: Skin: NOS
6%
Memory loss
1%
Dyspnea (shortness of breath)
1%
Hemorrhage-Other
1%
Ataxia (incoordination)
1%
Mood alteration-depression
1%
Pain-Other
100%
80%
60%
40%
20%
0%
Study treatment Arm
Prophylactic Cranial Irradiation (PCI)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Patients with Small Cell Lung Cancer (SCLC)Experimental Treatment1 Intervention
This protocol will include participants with newly diagnosed extensive stage (stage IV) small cell lung cancer with tissue collected from the primary lung tumor, or metastatic sites outside of the liver or biliary system.

Find a Location

Who is running the clinical trial?

Tempus AILead Sponsor
16 Previous Clinical Trials
17,854 Total Patients Enrolled
AstraZenecaIndustry Sponsor
4,352 Previous Clinical Trials
288,646,759 Total Patients Enrolled
Tempus LabsLead Sponsor
16 Previous Clinical Trials
18,354 Total Patients Enrolled
~20 spots leftby Mar 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top